When an APOB containing lipoprotein binds to an LDL receptor and becomes internalized into the liver, the whole thing comes in. Instead of this PCSK9 protein breaking that receptor down, you block that and it gets recycled. So that's why when you give someone a PCSK9 inhibitor, their APOB or LDL cholesterol levels go down. LP little A is kind of a subtype of LDL with an extra protein on it that makes it particularly thrombotic, arthrogenic.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode